title: Successful vancomycin desensitization in a patient with end-stage renal disease and anaphylactic shock to vancomycin.
abstract: OBJECTIVE
  To report successful desensitization in a patient with a history of end-stage renal disease (ESRD) and anaphylactic shock after receiving vancomycin.
  
  
  METHODS
  A 47-year-old white woman with a history of ESRD was admitted to the hospital reporting persistent nausea, vomiting, and diffuse abdominal pain. She had developed anaphylactic shock after exposure to vancomycin 3 years prior to this hospitalization. The patient's hospital course was complicated by septic shock and positive blood cultures for methicillin-resistant Staphylococcus epidermidis. The patient tolerated vancomycin desensitization and received intravenous vancomycin 100 mg/d for 21 days.
  
  
  CONCLUSIONS
  The desensitization protocol used in this report allows for gradual increases in vancomycin serum concentrations, avoiding peak and trough concentrations that occur with intravenous boluses. Maintaining the desensitized state is dependent on the continuous presence of the antigen with a return of clinical sensitivity after drug discontinuation. The vancomycin desensitization protocol and subsequent dosing strategy was used to ensure the continuous presence of vancomycin at steady-state concentrations to prevent the return of anaphylactic sensitivity.
  
  
  CONCLUSIONS
  Desensitization was successful in a patient with ESRD and history of anaphylactic shock to vancomycin.
authors.affiliation: Pharmacy Department, Indiana University Hospital of Clarian Health, Indianapolis 46202, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Sorensen
authors.forename: S L
authors.initials: SL
authors.lastname: Wise
authors.forename: J A
authors.initials: JA
authors.lastname: al-Tawfiq
authors.forename: J L
authors.initials: JL
authors.lastname: Robb
authors.forename: H E
authors.initials: HE
authors.lastname: Cushing
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced*; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic; D008875:Middle Aged; D018805:Sepsis / Q000188:drug therapy; D014640:Vancomycin / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin